InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,244.00
(
1.57%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.17
(
0.00%
)
Bitcoin
62,939.62
(
-1.25%
)
Post# of 251620
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119499
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 183056

Thursday, 10/30/2014 5:49:30 PM

Thursday, October 30, 2014 5:49:30 PM

Post# of 251620
FDA advisory panel endorses Edoxaban for AF/stroke prevention by 9-1 vote:

http://in.reuters.com/article/2014/10/30/us-daiichi-sankyo-fda-idINKBN0IJ2KR20141030

Daiichi Sanko has a lot of work to do insofar as Xarelto, Eliquis, and (to a lesser extent) Pradaxa are well established in this indication. Edoxaban, like Xarelto and Eliquis, is a Factor Xa inhibitor.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up